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The presence of seemingly unexplained peripheral neu-
ropathy in a sick patient warrants persistent delving into the 
medical, social and especially occupational history. Bearing 
this in mind, we have an interesting case to present. 
Case Presentation 
The patient was a 36-year-old man who had been diag-
nosed as having peptic ulcer disease and the presence of heli-
cobactor pylori in an EGD biopsy specimen 3 months earlier. 
He was admitted to the hospital because of an acute onset of 
epigastric pain that began that morning. The patient was 
admitted to the regular medical ward and the gastroenterolo-
gist who had been following the patient for his PUD was con-
sulted. The gastroenterologist recommended medical therapy 
empirically for the ulcers. He believed the patient required a 
stat EGD since a follow-up EGD done 2 weeks earlier had 
been negative for ulcers. An H2 blocker medication for heli-
cobactor pylori was started. He required 75 mgs of meperi-
dine i.m. for his severe abdominal pain. 
The abdominal pain persisted; further work-up included 
an upper GI series, which showed no ulcers but did show 
some evidence of duodenitis, and a CT scan of the abdomen 
that was negative. Laboratory work-up included stool cul-
tures, pancreatic enzymes, sickle cell screen, hepatitis screen, 
porphyria screen, liver function tests, and ESR, all of which 
were negative. 
The patient described his abdominal pain as being inter-
mittent, excruciating, either localized in the epigastric region, 
the left lower quadrant, or sometimes everywhere; it was 
associated with nausea but no vomiting. On physical exami-
nation, there was no rebound or guarding but mild to moder-
ate tenderness to palpation could be demonstrated. He contin-
ued to complain of abdominal pain throughout his hospital 
course, and he required a constant regimen of pain control 
including Demerol, Dilaudid, Darvocet, Percocet, and even a 
PCA pump with low-dose morphine. 
The patient's abdominal pain work-up was completed 
without any significant findings. He was discharged to outpa-
tient care with pain medication, an H2 blocker, and medica-
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tion for helicobactor prophylaxis. He was instructed to return 
for follow-up in a clinic in a couple of days. 
When he reported to the clinic, he still complained of 
severe abdominal pain and had taken all of the pain 
medicine given at discharge. During this visit, a 24-hour 
urine heavy-metal screen was obtained. The report came 
back negative for lead and mercury but was positive for 
arsenic at 865 meg/liter (normal < 100). To confirm this 
urine arsenic finding, pubic hair analysis for arsenic was 
done and it also returned positive at 5.6 microgram/gram of 
hair (* 75% have less than 0.03 to 0.3 mcg/gm hair, 20% 
are between 0.3 to 3mcg/gm hair, 5 % are up to 4 mcg/gm 
hair.) A more detailed diet and work history was obtained. 
He was treated as an outpatient for arsenic toxicity with 
penicillamine. However, he presented himself again to the 
clinic with the same, severe abdominal pain before penicil-
lamine therapy. He was again admitted to the hospital for 
treatment with dimercaprol or BAL (British Anti-Lewisite), 
which entails intramuscular injections every 4 hours. The 
patient improved clinically, the repeat 24-hour urine-
arsenic level was < 35 meg/liter, and the arsenic content in 
the hair was down to 1.3 meg/gram of hair. 
The patient continued to be followed closely as an out-
patient. His abdominal pain reoccurred with a fluctuating 
course. Additional work-up revealed a negative colonoscopy, 
a negative nerve conduction test and electromyelogram and 
negative lab tests, including urine and hair arsenic levels. 
Many questions were raised: Was this definitely arsenic toxi-
city? If so, what was the source of the arsenic? Were the GI 
symptoms related to the arsenic toxicity? 
The Sources of Arsenic 
Arsenic is ubiquitous in nature and the 20th most common 
element in the earth's crust1• Arsenic is present in saltwater 
and seafood. Fish and shellfish contain a relatively high con-
centration of arsenic; this is relatively nontoxic and is readily 
excreted through urine2• Urinary arsenic levels may be 
increased as much as tenfold after eating a large seafood 
meal1• Notably, arsenic also is found in well water3• 
Historically arsenic has been used in medicines• and cur-
rently organic arsenicals are still being used in the treatment 
of certain protozoan diseases. It is also an ingredient in vet-
erinary medicine'. Arsenic has been used in feed for poul-
try, cattle and swine to improve the nutritional status of ani-
mals6. Furthermore, arsenic has been a constituent of drugs 
such as opium'. Industrial use of arsenic has been a major 
source of worker exposure. In 1973, the National Institute for 
Occupational Safety and Health estimated that 1.5 million 
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people were potentially exposed to arsenic during the course 
of their work7 • Smelter workers were at increased risk for 
potential arsenic exposure. A study of smelter workers indi-
cated increased mortality-mostly secondary to lung cancer-
proportional to their exposure to arsenic8• 
Arsenic is used in many commercial products; it is used as 
an additive in metal alloys to increase hardening and heat 
resistance, in the manufacture of glass, in wood preservatives, 
in lead-plating, and in various types of paints including fresco, 
tempera, watercolor, and oil paints5. 
Arsenic also is used in making silicon microfilm•, light-
emitting diodes in watches9, and in salt-impregnated materials 
for fires to produce multicolored flames10• Arsenic also plays a 
major role in agriculture: Pesticides, herbicides, fungicides, 
weed/tree killers, fly killers, rodenticides all contain arsenic 
because of its effectiveness and low cost". The use of arsenic 
as a desiccant of cotton comprises 15% of the U.S. market for 
arsenic trioxide!. Significantly in our case, arsenic trioxide is a 
commonly used agent in the treatment of wood against ter-
mites. The wood used in the construction industry in Hawaii 
often is pressure-treated with this compound. 
Clinical Manifestations of Toxicity 
The clinical manifestations of arsenic toxicity vary wide-
ly and are dependent on the duration of exposure, level of 
the dose (if ingested), whether intake is acute or chronic, and 
on the chemical compound of the arsenic. The 3 forms of 
toxic arsenic are the trivalent salt, pentavalent salts, and 
arsine gas 12. Elemental arsenic is not toxic 12. Pentavalent 
salts are found in the earth's crust and are prevalent in foods; 
they are less toxic than the trivalent salts which tend to accu-
mulate in the body more readily. Arsine gas is the most toxic 
and is frequently fatal. 
Acute toxicity can occur with arsine gas poisoning or with 
massive doses of ingested arsenic. The symptoms of acute 
arsenic intoxication are apparent within 30 to 60 minutes, but 
death usually does not occur until approximately 24 hours lat-
er13. A garlicky odor in the breath and stool may be apparent. 
The patient might complain of a metallic taste in the mouth14. 
Arsine gas poisoning is usually overwhelming and usually 
leads to death. Initial symptoms include: Fever, headache, 
nausea, vomiting, epigastric pain, dysuria, and explosive diar-
rhea. Hemolytic anemia also occurs as the arsenic binds to red 
blood cells; cyanosis and hypoxia could ensue. Shock with 
intractable vascular collapse and encephalopathy can occur, 
and myocardial damage and bone marrow suppression. 
Acute ingestion of arsenic is usually more insidious in it's 
manifestations. Severe gastrointestinal involvement is the 
hallmark of acute ingestion. Symptoms can include nausea, 
vomiting, profuse watery diarrhea and colicky abdominal 
pain 14. Dysphagia secondary to the toxic damage to the 
esophageal lining can occur, as well as dehydration and elec-
trolyte abnormalities. Other gastrointestinal manifestations 
include jaundice, hepatomegaly, hepatic enzyme abnormali-
ties and even pancreatitis. 
Almost every organ system can be involved. 
Cardiorespiratory findings include EKG abnormalities such as 
QT prolongation, nonspecific ventricular arrythmias and sag-
ging of the ST segment15·16·17 • Pulmonary edema, bronchial 
pneumonia and pericarditis can occur. Neurological manifes-
tations include seizures, encephalopathy, headache, vertigo, 
and a sensorimotor neuropathy which occurs 10 days to 3 
weeks after the exposure13. Hematologically, anemia is the 
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most common (normochromic-normocytic, hemolytic). Other 
findings include leukopenia, aplastic anemia, leukemia, and 
thrombocytopenia14. Renal failure and proteinuria secondary 
to cortical necrosis can occur and a case of severe rhabdomy-
olysis with the CPK elevated to 31,350 U/L in a fatal arsenic 
trioxide poisoning has been reported13. 
Chronic arsenic exposure is associated with several other 
abnormalities in addition to some of the features of acute 
arsenic poisoning. One of the most characteristic abnormali-
ties of chronic toxicity involves the skin. Dermatologic mani-
festations include: Hyperpigmentation (arsenic melanosis), 
brawny desquamation, hyperkeratosis (especially of the palms 
and soles), alopecia, dermatitis, folliculitis and "rain drop" 
depigmentation12·14. Skin cancers have been known to appear 
in 5% to 10% of people with chronic exposure to arsenic. The 
cancers can appear 5 to 25 years later and appear mostly on 
the trunk and upper extremities. Histologically, the lesion can 
be either squamous cell or basal cell12. 
The content of arsenic in nails and hair has been used for 
diagnosis of chronic exposure. Aldrich-Mees lines (white 
transverse bands across fingernails and toenails) can be seen 4 
to 6 weeks after exposure 14·19. An elevated concentration of 
arsenic in the hair is a sign of chronic toxicity. The upper limit 
of normal content in individuals not exposed to arsenic is said 
to be approximately 5mg!k:g but the arsenic content in hair can 
vary depending on environmental and nutritional factors20 • 
Other manifestations of chronic toxicity include squamous 
cell carcinoma of the lung and liver abnormalities such as 
hepatocellular carcinoma, post necrotic cirrhosis and heman-
gioendothelioma. In Taiwan, peripheral vascular (Blackfoot) 
disease has been associated with high exposure to arsenic in 
well water12• 
Other Reported Cases in Hawaii 
In the search for other cases of arsenic toxicity in Hawaii, 
we contacted the pathology departments of most of the 
major hospitals in Oahu, as well as Smith Kline Laboratory, 
Diagnostic Laboratory Services of Hawaii and the Hawaii 
Department of Health. There were several cases reported to 
the Department of Health, but all of the reports were dis-
missed as high urinary arsenic levels secondary to seafood 
ingestion rather than to arsenic toxicity. One patient at 
Kaiser Permanente Medical Center presented with peripheral 
neuropathy. Work-up revealed elevated urinary arsenic lev-
els 1300 mcgll and 372 mcg/1 (normal < 100 megA) and an 
elevated hair arsenic level of 151 mcg!IOO gram of hair (nor-
mal 0-65 mcg/lOOgram). The source of his arsenic exposure 
was unknown. 
As a result of our investigation, there were no other reports 
of arsenic toxicity in Hawaii that were documented by posi-
tive urine and hair analysis. 
Diagnosis and Treatment 
A carefully detailed history regarding the possible source 
of the exposure is extremely important when considering 
arsenic toxicity as a diagnosis. In addition to the history and 
physical, laboratory tests are useful-some more than others. 
Serum arsenic level is often not helpful because of rapid clear-
ance. A 24-hour urine collection is useful, especially for docu-
menting acute arsenic intoxication. Arsenic is excreted 
through the kidney at a rate of 30% to 70% in a 24-hour peri-
od21. Toxic levels might be missed if there is a delay between 
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the time of exposure and the time of evaluation. In acute 
ingestion, abdominal radiographs might be useful because 
arsenic, a heavy metal, will show up radiographically22 • 
In chronic exposure, analysis of nails and/or hair is help-
ful though the arsenic content of hair is affected by nutrition-
al and environmental factors. Arsenic is present in hair and 
nails 2 to 4 weeks after ingestion5• One paper reported analy-
sis of arsenic in other biological fluids, such as gastric and 
vesicular fluids that accumulate higher levels as compared to 
pleural and pericardia! fluids 23 • There is no standardized 
value or a definitive test that diagnoses the arsenic toxicity 
absolutely, although urine arsenic levels greater than 200 
mcg/1 and hair arsenic levels greater than 65mcg/1 00 grams 
of hair can be used as a presumptive evidence of an 
increased arsenic load21 • 
Treatment should be directed in 2 ways: Chelation thera-
PY to increase excretion of arsenic and supportive and symp-
tomatic therapy for the organ systems involved in the toxici-
ty, The Poisindex24 at the Hawaii Poison Center recommends 
the following treatment: "For acute massive arsenic inges-
tion, cardiac and respiratory support using compressors and 
ventilators, as in any other critical patient is recommended. 
This should be followed by gastric decontamination with 
gastric lavage and an absorbent such as activated charcoal, or 
a cathartic magnesium citrate or a sorbitol solution. 
Alkalinization of the urine might be helpful in preventing 
deposition of red blood cell breakdown products in renal 
tubular cells when hemolysis is occurring." 
Chelation therapy is recommended in symptomatic 
patients known to have ingested arsenic and in asymptomatic 
patients who have a documented urinary arsenic level greater 
than 200 mcg/1. Dimercaprol is the first line of treatment. 
The dose ranges from 3 to 5 mgAkg i.m. every 4 to 12 hours 
until the symptoms abate or another chelator is substituted. 
One author recommends tapering the dose but continuing 
administration of dimercaprol until the urinary excretion is 
less than 50mcg/24 hours1• Dimercaprol is an effective chela-
tor but has some disadvantages. The intramuscular injections 
can be painful, and there are many adverse effects such as 
mild systemic shock, tachycardia, hypertension, vomiting, 
convulsions, headache, nausea, vomiting and anorexia. A 
prior injection with epinephrine might alleviate some of sys-
temic effects25 • D-Penicillamine is an oral chelator found to 
be effective. The usual dose is 25 mg/kg given 4 times a day 
up to one gram/day. The 3 short-term adverse effects have 
not been reported, but long-term effects of penicillamine 
have included fever, leukopenia, thrombocytopenia, 
eosinophilia and renal toxicity. Another agent, 2,3-dimercap-
tosuccinic acid (DMSA), appears to be a promising method 
of treatment, although currently it is approved only for use in 
lead-poisoning in children. DMSA for adult arsenic treat-
ment is still under investigation and, therefore, must be 
obtained from the Regional Poisons Unit27 • 
Summary 
As mentioned at the beginning of this article, many ques-
tions were raised in our one particular case including the 
problem of verifying true arsenic toxicity and in determining 
the source of the exposure. In our case, there was a markedly 
elevated concentration of arsenic in samples of pubic hair 
and in the sample of urine. 
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While arsenic toxicity can present with GI symptoms, we 
felt that in this particular case the association of the abdomi-
nal pain with arsenic toxicity was unlikely. For one, the 
patient's symptoms persisted despite apparent adequate treat-
ment for arsenic toxicity. Also, the usual symptom of chron-
ic arsenic toxicity is peripheral neuropathy (which was not 
documented in our case) and not abdominal pain. After the 
exhaustive diagnostic workup, we felt that this patient had 
irritable bowel syndrome and that the discovery of arsenic 
toxicity was serendipitous. 
In regards to the etiology of the toxicity, the patient's 
occupation involved working in the construction industry for 
a number of years. He indicated a definite exposure to ter-
mite-treated wood throughout that period. Wood for building 
houses, etc. is commonly pressure-treated with an arsenic-
based compound; therefore, this source of occupational 
exposure appears to be a likely one. 
Another remotely possible source was the ingestion of 
contaminated illicit drugs. Cases of the use of illicit drugs 
laced with various toxic agents such as cyanide and strych-
nine have been reported. Although our patient required anal-
gesics not commensurate with his symptoms, he categorical-
ly denied any use of "street" drugs. The random urine drug 
screen for such was negative. The patient also claimed he 
was subjected to a series of random urine drug screens at the 
job and all had been negative. 
In conclusion, our patient represented what appeared to be 
a well-documented case of arsenic toxicity. However, further 
investigation was needed as to whether the source might 
have been prolonged exposure to chemically treated wood. 
In that eventuality, medical practitioners need to consider 
arsenic toxicity in their differential diagnosis of patients pre-
senting, in particular, with peripheral neuropathy of 
unknown etiology, and should obtain an appropriate occupa-
tional history. 
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with G-6-PD defioe~cy,. has been ,reported_; a. causal ~elahor:t-Ship to ena1apnl has not been est.abhshed 
Nt.'fWib Sy;;tem/PsyciiiRfnc Dep~lon,. contus1on, atax1~, penpheral neuropathv (e.g., paresthes1a, dyses-
t~esia); Urogc111tal: Renal fail_u~, ohguna, renal dysfunction (see ~RECAL~,ONS), flank pain, gynL'COmas-
ha; Rcsp1ratonr Pulmonary mfi!trates, b~onch~)Spas~, pneumoma, bronch!.hs, rh~orrh~a, sore throat and 
hoarsenes.<>, a·sthma, upper respiratory mfechon; Skm: Exfoliative dern:ahti.-,, tox~c ep1dermal. necrolysis, 
Stevens-Joh!1~Jn svn~rome, herpes zoster, .erythema mu!tifonne, urti~ana, pemph~gus, alopec1a, tl':15hmg, 
pho~nsihvitv; :)peoa!SCI!scs: Blurred vis1on, taste alteration, .anosm1a~ conJunchvlhs, dry eves, teanng. 
Miscel!aneoJi~: A ~ymptof!l complex has ~n repor.t~ whKh '?av md~~e a positive A~.A, an e!e\.·a.t-
ed ervthr~vte sed1mentahon rate, ~~thralgJa/arthntJs, mva!gJJ(mv.ostt!s, fever, seros1tJs, vascuhhs, 
leukOCvtt)SlS, eosinoph!!ia, photosens!hvity, rash and other dennatologJC manifestations 
Fcta1/Neol/alal Mo:builtyand Mortality: See WAR!\'INGS, Pregnancy, Enalapnl t'r1alcatc. Fetal/Neonatal 
Morbuhtv and Mortal Jill 
. Hy~r6chl:Jrotlua::~e_:_Body qs 11 Whoh:: \:\'~a~ess; D1gcst!1\': Pancreati~s, jaund!ce (intr~epatic cholesta~c 
latmdJCe),.sJa!ademhs~ crampmg, gastnc 1mtatmn,. anorexw; Hcmafi4ogic: Aplashc anemJa, .aw~nulocytos.ts, eukopema, hen:olyhc an~~ia, thrombocytopema; HypeNCIISlill'Ify: Purpu~a, pho.tosens.ttlvtty, urhca~~· 
necrotizing angittis {vascultbs and ~utaneo~ vasculitis), fever, respiratory d1stress mdudmg pneumombs 
and pulmonary edema, anaphylachc reactions; Musculoskeletal: Muscle spasm; Ncnm_b Sy~tcm/Psycluatnc 
Rest~essness; R.i.'111.1(: Rena! failure, renal dysfunction, int~rstitial nephri~s ~see w.ARNI~GS~; Skm: Erythema 
n:uJhform.e n~clu?mg Stewns-Jo~son syndro_n:e, exfohatiw.de. nnatihs mdudmg toxJC epidermal necroly-
SJs, alopeaa; Spcoal5t'IN'S: T rans1ent blurred \'JSJon, x,mthops1a 
~ Based on patient weight of 50 kg 
For more dctmled n~formafwn. consult your DuPo11t Pharma Rcprc~mtafti.'C or see Prc~mbms ii!Amnatwn 
Dist. bv 
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